Nose‐to‐Brain Delivery of Circular RNA SCMH1‐Loaded Lipid Nanoparticles for Ischemic Stroke Therapy

Y Yanpeng Jia (Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China) L Lian Xu S Shuo Leng (Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China) Y Yan Sun X Xinxin Huang (State Key Laboratory of Bioinspired Interfacial Materials Science, Institute of Functional Nano & Soft Materials (FUNSOM)) Y Yu Wang H Hui Ren G Guanlong Li (Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China) Y Ying Bai (Beijing Key Laboratory of Environmental Science and Engineering, School of Materials Science and Engineering) Z Zhongkun Zhang (1Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA) B Bing Han L Ling Shen M Minzi Ju L Lehui Chen (Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China) H Honghong Yao

Abstract

Abstract Ischemic stroke represents one of the leading cerebrovascular diseases with a high rate of mortality and disability globally. To date, there are no effective clinical drugs available to improve long‐term outcomes for post‐stroke patients. A novel nucleic acid agent circSCMH1 which can promote sensorimotor function recovery in rodent and nonhuman primate animal stroke models has been found. However, there are still delivery challenges to overcome for its clinical implementation. Besides, its effects on post‐stroke cognitive functions remain unexplored. Herein, lipid nanoparticle circSCMH1@LNP1 is established to deliver circSCMH1 and explore its therapeutic efficacy comprehensively. Distribution experiments demonstrate that intranasal administration of circSCMH1@LNP1 significantly increases circSCMH1 distribution in the peri‐infarct region and reduces its non‐specific accumulation in other organs compared to intravenous injection. Therapeutic results indicate that circSCMH1@LNP1 promotes synaptic plasticity, vascular repair, neuroinflammation relief, and myelin sheath formation, thereby achieving enhanced sensorimotor and cognitive function recovery in post‐stroke mice. In conclusion, this research presents a simple and effective LNP system for efficient delivery of circSCMH1 via intranasal administration to repair post‐stroke brain injury. It is envisioned that this study may bridge a crucial gap between basic research and translational application, paving the way for clinical implementation of novel circSCMH1 in post‐stroke patient management.

Article Details

Volume / Issue Vol. 37, Issue 19
Published May 01, 2025
ISSN 0935-9648
Publisher Unknown Publisher

Journal Info

Advanced Materials

Unknown Publisher

ISSN: 0935-9648 Physical Sciences

Authors (15)

Y

Yanpeng Jia

Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China

L

Lian Xu

S

Shuo Leng

Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China

Y

Yan Sun

X

Xinxin Huang

State Key Laboratory of Bioinspired Interfacial Materials Science, Institute of Functional Nano & Soft Materials (FUNSOM)

Y

Yu Wang

H

Hui Ren

G

Guanlong Li

Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China

Y

Ying Bai

Beijing Key Laboratory of Environmental Science and Engineering, School of Materials Science and Engineering

Z

Zhongkun Zhang

1Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

B

Bing Han

L

Ling Shen

M

Minzi Ju

L

Lehui Chen

Department of Pharmacology Jiangsu Provincial Key Laboratory of Critical Care Medicine School of Medicine Southeast University 87 Dingjiaqiao Road Nanjing Jiangsu 210009 China

H

Honghong Yao